基本信息
浏览量:7
职业迁徙
个人简介
My research focuses on a novel approach towards targeted cancer therapy. While new therapies targeting molecular cancer biomarkers have shown the potential benefits of targeted therapy, their breadth is limited, as very few truly tumor-specific biomarkers exist. In the Engelman Lab at Yale University we are targeting a different sort of marker: acidity. Solid tumors produce an acidic extracellular environment as a result of ischemia and anaerobic, glycolytic metabolism. Unlike expressed markers, acidity is a physiological consequence of cancerous growth and is present in most cancers. By designing therapeutics to take advantage of tumor acidity to control the uptake of toxic chemotherapeutic agents, our aim is to lower the side effects of chemotherapy, enabling more tolerable and more effective cancer treatments.
Based on my work in the Engelman Lab, I have invented a novel platform for tumor-targeted drug delivery. In 2018, I aim to translate these advances to a pharmaceutical startup in Connecticut: Cytosolix, Inc.
Based on my work in the Engelman Lab, I have invented a novel platform for tumor-targeted drug delivery. In 2018, I aim to translate these advances to a pharmaceutical startup in Connecticut: Cytosolix, Inc.
研究兴趣
论文共 9 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn